Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas

BACKGROUND: MiT family translocation renal cell carcinoma (TRCC) is a rare and aggressive subgroup of renal cell carcinoma harboring high expression of c-MET. While TRCC response rates to VEGF receptor tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors are limited, efficacy of caboza...

Descripción completa

Detalles Bibliográficos
Autores principales: Thouvenin, Jonathan, Alhalabi, Omar, Carlo, Maria, Carril-Ajuria, Lucia, Hirsch, Laure, Martinez-Chanza, Nieves, Négrier, Sylvie, Campedel, Luca, Martini, Dylan, Borchiellini, Delphine, Chahoud, Jad, Lodi, Massimo, Barthélémy, Philippe, Hasanov, Elshad, Hahn, Andrew W, Gil, Thierry, Viswanathan, Srinivas R, Bakouny, Ziad, Msaouel, Pavlos, Asim Bilen, Mehmet, Choueiri, Toni K, Albiges, Laurence, Tannir, Nizar M, Malouf, Gabriel G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249266/
https://www.ncbi.nlm.nih.gov/pubmed/35979929
http://dx.doi.org/10.1093/oncolo/oyac158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249266/
https://www.ncbi.nlm.nih.gov/pubmed/35979929
http://dx.doi.org/10.1093/oncolo/oyac158

Ejemplares similares